Nuevo topico para lesiones premalignas.

Phase 3 Trials Of Ointment Show 100% Clearance Of Precancerous Lesions.

Fierce Biotech (7/26, Hale) reports Athenex reported that two phase 3 trials of its skin ointment for precancerous lesions achieved 100 percent "clearance of actinic keratosis growths within 60 days, including in the face and scalp." The "placebo-controlled studies randomized a total of 702 adult participants, with the 1% ointment, KX-01, being applied once daily for five days." The ointment is a "dual Src kinase and tubulin polymerization inhibitor." The company says Src "helps regulate aspects of tumor growth and metastases, while inhibiting tubulin polymerization activity can halt progression of the cell cycle at mitosis. The small molecule KX-01 binds for both targets using a novel site."